According to Biocon, the insulin market in Malaysia is pegged at around $40 million including sales from tenders and retail. Insulin glargine and breast cancer drug trastuzumab are major contributors in terms of sales for Biocon. Insulin glargine will initially be manufactured and shipped to Malaysia from Biocon’s Bengaluru facility, before the new facility starts producing it. The company last week said its partner FUJIFILM Pharma Co. Ltd has launched insulin glargine in Japan. The Malaysian approval comes months after Japanese approval for Biocon’s insulin glargine, providing a fillip to the company’s efforts of launching biosimilars in other markets.

Source: Mint July 22, 2016 16:55 UTC